BOSTON, March 20, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
Elevation Oncology discontinues EO-3021 development due to insufficient efficacy in phase 1 trial, despite favorable safety profile. EO-3021 trial showed a 22.2% objective response rate and 72.2% ...
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination ...
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results